Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...

January 29, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for ...

Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...

In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

BioAge Labs, Inc., et al., No. 25-cv-196 ... BioAge stated that it was collaborating with Eli Lilly and Company ("Lilly") in ...

New York, New York-- (Newsfile Corp. - January 16, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

BioAge Labs, Inc., et al., No. 25-cv-196 ... BioAge stated that it was collaborating with Eli Lilly and Company (“Lilly”) in connection with STRIDES, and that Lilly would be advising and assisting on ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Eli Lilly started 2024 on a strong note but struggled ... could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off AbbVie in 2013, Humira was the new ...